secwatch.observer — SEC 8-K summary
======================================

Issuer:     Elanco Animal Health Inc (ELAN)
CIK:        0001739104
Form:       8-K
Filed at:   2022-04-13T23:59:59+00:00
Accession:  0001104659-22-045250
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 5.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elanco spins out microbiome platform into BiomEdit with $40M funding; tenders $406M of 2023 notes
--------------------------------------------------------------------------------

- Elanco launches BiomEdit, a microbiome innovation company, with $40M Series A from Viking Global and Anterra Capital.
- Elanco contributes IP and pipeline to BiomEdit; retains non-voting equity; combined Elanco/Ginkgo ownership ~40% fully diluted.
- Tender offer: $406M (54.19%) of 4.272% notes due 2023 tendered; cap raised to $406M; early acceptance at $1,035 per $1,000.
- BiomEdit to leverage Ginkgo's cell programming platform for probiotics, bioactives, and engineered microbial medicines.
- Aaron Schacht named CEO of BiomEdit; enters consulting agreement with Elanco at $250/hour for advisory role.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1739104/000110465922045250/0001104659-22-045250-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1739104/000110465922045250/tm2212574d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-045250

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer